Skip to Content
Merck
  • Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation.

Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation.

Scientific reports (2020-01-22)
Sylwia Jones, Peter J King, Costin N Antonescu, Michael G Sugiyama, Amandeep Bhamra, Silvia Surinova, Nicos Angelopoulos, Michael Kragh, Mikkel W Pedersen, John A Hartley, Clare E Futter, Daniel Hochhauser
ABSTRACT

Antibody combinations targeting cell surface receptors are a new modality of cancer therapy. The trafficking and signalling mechanisms regulated by such therapeutics are not fully understood but could underlie differential tumour responses. We explored EGFR trafficking upon treatment with the antibody combination Sym004 which has shown promise clinically. Sym004 promoted EGFR endocytosis distinctly from EGF: it was asynchronous, not accompanied by canonical signalling events and involved EGFR clustering within detergent-insoluble plasma mebrane-associated tubules. Sym004 induced lysosomal degradation independently of EGFR ubiquitylation but dependent upon Hrs/Tsg101 that are required for the formation of intraluminal vesicles (ILVs) within late endosomes. We propose Sym004 cross-links EGFR physically triggering EGFR endocytosis and incorporation onto ILVs and so Sym004 sensitivity correlates with EGFR numbers available for binding, rather than specific signalling events. Consistently Sym004 efficacy and potentiation of cisplatin responses correlated with EGFR surface expression in head and neck cancer cells. These findings will have implications in understanding the mode of action of this new class of cancer therapeutics.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Erlotinib hydrochloride
Sigma-Aldrich
hEGF, EGF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Cytochalasin D, Zygosporium mansonii, InSolution, ≥98%, 10 mM in DMSO, A cell-permeable fungal toxin
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
CelLytic M, Cell Lysis Reagent, Suitable for Mammalian cell lysis and protein solubilization.
Sigma-Aldrich
MG-132, InSolution, ≥98%, 10 mM, reversible proteasome inhibitor
nProtein A Sepharose 4 Fast Flow, Cytiva 17-5280-01, pack of 5 mL
Sigma-Aldrich
SB 203580, SB 203580, CAS 152121-47-6, is a highly specific, potent, cell-permeable, selective, reversible, and ATP-competitive inhibitor of p38 MAP kinase (IC₅₀ = 34 nM in vitro, 600 nM in cells).
Sigma-Aldrich
Bafilomycin A1, Streptomyces griseus, Bafilomycin A1, CAS 88899-55-2, acts as a highly potent and specific inhibitor of vacuolar-type H+-ATPase (Ki = 500 pM). Blocks the fusion of autophagosome with lysosome.
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, ascites fluid, clone B-5-1-2